Insights

  • Date

  • Content Type

  • Reset

Article

A New Model for Novel Biopharma

24.02.22

By Elena Meurer

Novel and Advanced Therapies have made great strides over the past decade but that means…
Read More

Blog

Happily ever after: Why scientific due diligence is key to a successful M&A marriage

23.02.22

By Dr. Diane Seimetz

Why scientific due diligence is key to a successful M&A

Read More

Article

How MHRA’s Innovative Licensing Access Pathway seeks to improve patient access

17.02.22
By Christian K. Schneider, MD

The MHRA’s objective was to develop an Innovative Licensing and Access Pathway (ILAP) that offers...
Read More

Article

The Biotech Revolution: The manufacturing & quality implications of cell and gene therapies

15.02.22
By Elena Meurer at Biopharma Excellence

The market for Advanced Therapies has come a long way in the last decade,...
Read More

Article

Novel Biopharma: What Lies Ahead?

15.02.22
By Elena Meurer, Principal Consultant

Advanced Therapies have come a long way over the past decade. Some cell and gene...
Read More

Blog

Extracellular vesicles in drug delivery – Understanding their potential and challenges

11.02.22

By Jörg Schneider

The field of extracellular vesicles is a nascent and rapidly..

Read More

We are now Cencora PharmaLex 

PharmaLex is now part of Cencora, a leading global healthcare company with a foundation in pharmaceutical distribution. In 2024 and beyond PharmaLex and all the companies in PharmaLex family will begin a journey to becoming Cencora as well. Cencora brings the companies and services together under one new name. The name will change, but the level of attention and service you receive remains the same.  

Know more